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Abstract
Background:  Thromboxane B2 (TXB2) and superoxide anion (O2
-) are neuroinflammatory
mediators that appear to be involved in the pathogenesis of several neurodegenerative diseases.
Because activated-microglia are the main source of TXB2 and O2
- in these disorders, modulation of
their synthesis has been hypothesized as a potential therapeutic approach for neuroinflammatory
disorders. Marine natural products have become a source of novel agents that modulate
eicosanoids and O2
- generation from activated murine and human leukocytes. With the exception
of manzamine C, all other manzamines tested are characterized by a complex pentacyclic diamine
linked to C-1 of the β -carboline moiety. These marine-derived alkaloids have been reported to
possess a diverse range of bioactivities including anticancer, immunostimulatory, insecticidal,
antibacterial, antimalarial and antituberculosis activities. The purpose of this investigation was to
conduct a structure-activity relationship study with manzamines (MZ) A, B, C, D, E and F on
agonist-stimulated release of TXB2 and O2
- from E. coli LPS-activated rat neonatal microglia in vitro.
Results:  The manzamines differentially attenuated PMA (phorbol 12-myristate 13-acetate)-
stimulated TXB2 generation in the following order of decreasing potency: MZA (IC50 <0.016 µM)
>MZD (IC50 = 0.23 µM) >MZB (IC50 = 1.6 µM) >MZC (IC50 = 2.98 µM) >MZE and F (IC50 >10 µM).
In contrast, there was less effect on OPZ (opsonized zymosan)-stimulated TXB2 generation: MZB
(IC50 = 1.44 µM) >MZA (IC50 = 3.16 µM) >MZC (IC50 = 3.34 µM) >MZD, MZE and MZF (IC50 >10
µM). Similarly, PMA-stimulated O2
- generation was affected differentially as follows: MZD (apparent
IC50<0.1 µM) >MZA (IC50 = 0.1 µM) >MZB (IC50 = 3.16 µM) >MZC (IC50 = 3.43 µM) >MZE and
MZF (IC50 >10 µM). In contrast, OPZ-stimulated O2
- generation was minimally affected: MZB (IC50
= 4.17 µM) >MZC (IC50 = 9.3 µM) >MZA, MZD, MZE and MZF (IC50 > 10 µM). From the
structure-activity relationship perspective, contributing factors to the observed differential
bioactivity on TXB2 and O2
- generation are the solubility or ionic forms of MZA and D as well as
changes such as saturation or oxidation of the β  carboline or 8-membered amine ring. In contrast,
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the fused 13-membered macrocyclic and isoquinoline ring system, and any substitutions in these
rings would not appear to be factors contributing to bioactivity.
Conclusion: To our knowledge, this is the first experimental study that demonstrates that MZA,
at in vitro concentrations that are non toxic to E. coli LPS-activated rat neonatal microglia, potently
modulates PMA-stimulated TXB2 and O2
- generation. MZA may thus be a lead candidate for the
development of novel therapeutic agents for the modulation of TXB2  and O2
-  release in
neuroinflammatory diseases. Marine natural products provide a novel and rich source of chemical
diversity that can contribute to the design and development of new and potentially useful anti-
inflammatory agents to treat neurodegenerative diseases.
Background
The hallmark of brain inflammation is the activation of
glia, particularly microglia, the resident immune cells of
the brain [1]. Microglia activation in brain pathologies, as
caused by infectious diseases, inflammation, trauma,
brain tumors, ischemia and AIDS, may result in neuronal
injury and ultimately neurodegeneration [1]. Similar to
other tissue macrophages, when microglia become acti-
vated they release potentially neurotoxic mediators [2],
followed by sublethal and lethal injury to the central nerv-
ous system. The two different phenotypic forms of micro-
glia, namely the activated but nonphagocytic microglia
found in inflammatory pathologies and the reactive or
phagocytic microglia present in trauma, infection and
neuronal degeneration, appear to have the capacity to
express cell-surface receptors and release mediators of
inflammation, such as cytokines, coagulation factors,
complement factors, proteases, nitric oxide, eicosanoids
and reactive oxygen species [2].
Over the last three decades, the marine environment has
been demonstrated to be a source of novel therapeutic
agents, many of which have anti-inflammatory properties
[3]. We have previously shown that selected marine natu-
ral products modulate eicosanoids [4,5] and O2
- genera-
tion from activated rat [6] and human neutrophils [7], as
well as liver [8] and alveolar macrophages [9]. Based on
these observations we hypothesized that selected marine
natural products might potentially attenuate activated
brain microglia [2]. Since the discovery by Sakai and Higa
that the marine sponge-derived manzamine A (MZA) had
potent antitumor activity [10], there has been a sustained
interest in the chemistry [11] as well as the pharmacology
of the manzamines, a class of β -carboline marine-derived
alkaloids. More than 40 manzamine-type alkaloids have
been isolated from 9 different genera of marine sponges
from the Indian and Pacific Oceans, and in addition to the
antitumor activity [10], manzamines have been shown to
be immunostimulatory [12], insecticidal [13], antibacte-
rial[13], antimalarial [14], antiparasitic [15], antiviral
[16] and to possess antituberculosis activity [17].
In preliminary communications we have reported that
MZA, isolated from the Okinawan marine sponge Hali-
clona sp., potently inhibited TXB2 and O2
- generation by
activated rat neonatal microglia while showing very low
concomitant toxicity [18-20]. We now extend these previ-
ous communications by reporting the results of a struc-
ture-activity relationship study with manzamines A, B, C,
D, E and F on agonist-stimulated release of O2
- and TXB2
from LPS-activated rat neonatal microglia.
Results
Effect of manzamine A on LPS-activated neonatal brain 
microglia TXB2, O2
- and LDH release
As shown in Fig. 1, MZA has a pentacyclic diamine group
attached to the β -carboline moiety and it was tested as its
hydrochloride salt. As is shown in Fig. 2A, MZA potently
inhibited PMA-stimulated TXB2 generation (IC50 = 0.016
µM), with a maximum 95.5 % inhibition observed at 10
µM (MZA vs. vehicle, respectively 78.3 ± 45 vs. 1,413 ±
439 pg of TXB2 per 200,000 microglia per 70 min, P <
0.01, n = 4). Furthermore, as depicted in Fig. 3A, MZA
inhibited PMA-stimulated O2
- generation with an appar-
ent IC50 = 0.1 µM (MZA vs. vehicle, respectively 7.5 ± 1.8
vs.13.8 ± 1.9 nmol of O2
- per 200,000 microglia per 70
min, P < 0.01, n = 4). Significantly, increasing MZA con-
centrations to 10 µM resulted in O2
- inhibition of 55.9 ±
6.1 %, P < 0.01, n = 4.
In contrast, as shown in Fig. 2A, the effect of MZA on OPZ-
stimulated TXB2 generation was weaker (apparent IC50 =
3.16 µM), with a maximum 58 % inhibition at 10 µM
(MZA vs. vehicle, respectively 1,927 ± 474 vs. 4,504 ± 308
pg of TXB2 per 200,000 microglia per 70 min, P < 0.05, n
= 2). Similarly, as depicted in Fig 3A, MZA did not appear
to affect OPZ-stimulated O2
- generation even at 10 µM
(MZA vs. vehicle, respectively 9.5 ± 1 vs. 9.4 ± 0.7 O2
-
nmol per 200,000 microglia per 70 min, P > 0.05, n = 2).
As shown in Fig. 2A and 3A, the cytotoxicity of MZA to
neonatal brain microglia measured as LDH release was
not significantly different from controls even at 10 µM
(MZA vs. vehicle, respectively 21.3 ± 7 % vs. 13.9 ± 3.7 %
of total LDH released by 0.1 % Triton X-100 treated-BMC Pharmacology 2005, 5:6 http://www.biomedcentral.com/1471-2210/5/6
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The chemical structures of manzamines A, B, C, D, E and F Figure 1
The chemical structures of manzamines A, B, C, D, E and F. Manzamines are indole-derived alkaloids isolated from 
the marine sponges Haliclona sp. [10], Amphimedon sp. [66] and Xestospongia sp. [10,67]. Molecular weights are respectively = 
585.2, 550.8, 347.5, 591.3, 564.7, 580.8.
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Differential effects of manzamines A, B, C, D, E and F on PMA and OPZ-stimulated TXB2 generation by LPS-activated rat neo- natal microglia Figure 2
Differential effects of manzamines A, B, C, D, E and F on PMA and OPZ-stimulated TXB2 generation by LPS-
activated rat neonatal microglia. Rat neonatal microglia (200,000 cells/well) were activated with LPS (0.3 ng/mL) for 17 
hours. Manzamines were added 15 min before stimulation with either PMA (1 µM) or OPZ (0.5 mg/mL). After 70 min, agonist-
triggered TXB2 was measured as described in Materials and Methods. LDH release, indicator of cytotoxicity, was determined as 
described in Materials and Methods. Data are expressed as percentage of control TXB2 release triggered by either PMA (MZA: 
1,423 ± 439 pg TXB2 /70 min; MZB, C, D, E, F: 3,279 ± 281 pg TXB2 /70 min), or OPZ (4,504 ± 308 pg TXB2 /70 min). Data 
show mean ± SEM of indicated number (n) of experiments. * P < 0.05, ** P < 0.01.
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Differential effects of manzamines A, B, C, D, E and F on PMA and OPZ-stimulated O2
- generation by LPS-activated rat neona- tal microglia Figure 3
Differential effects of manzamines A, B, C, D, E and F on PMA and OPZ-stimulated O2
- generation by LPS-
activated rat neonatal microglia. Rat neonatal microglia (200,000 cells/well) were activated with LPS (0.3 ng/mL) for 17 
hours. Manzamines were added 15 min before stimulation with either PMA (1 µM) or OPZ (0.5 mg/mL). After 70 min, agonist-
triggered O2
- release was determined as described in Materials and Methods. LDH release, indicator of cytotoxicity, was meas-
ured as described in Materials and Methods. Data are expressed as percentage of control O2
- release triggered by PMA (MZA: 
13.8 ± 1.9 nmoles O2
-/70 min; MZB, C, D, E, F: 10.8 ± 0.6 nmoles O2
-/70 min), or OPZ (9.4 ± 0.7 nmoles O2
- /70 min). Data 
show mean ± SEM of indicated number (n) of experiments. * P < 0.05, ** P < 0.01.
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microglia, n = 6, P = 0.1735). This data suggests that the
effect of MZA on both PMA-stimulated TXB2 and O2
- may
be of a pharmacological nature.
Effect of manzamine B on LPS-activated neonatal brain 
microglia TXB2, O2
- and LDH release
MZB differs from MZA in having a tetracyclic diamine
complex and an epoxide ring system (Fig. 1). As shown in
Fig. 2B, MZB which was tested as a free base, was less
potent than MZA in affecting PMA-stimulated TXB2 gener-
ation (IC50 = 1.6 µM). MZB 10 µM reduced TXB2 release to
15.5 % of control (MZB vs. vehicle, respectively 546.3 ±
281 vs. 3,279 ± 281 pg of TXB2 per 200,000 microglia per
70 min, P < 0.01, n = 3). Similarly, as depicted in Fig. 3B,
MZB was less potent than MZA in affecting PMA-stimu-
lated O2
-  generation (IC50  = 3.16 µM). MZB 10 µM
reduced O2
- release to 20 % of control (MZB vs. vehicle,
respectively 2.14 ± 2.14 vs. 10.8 ± 0.6 nmol of O2
- per
200,000 microglia per 70 min, P < 0.01, n = 3).
As shown in Fig. 2B, MZB affected OPZ-stimulated TXB2
(IC50 = 1.44 µM) more than MZA. MZB 10 µM reduced
TXB2 generation to 25.6 % of control (MZB vs. vehicle,
respectively 1,160 ± 207 vs. 4,504 ± 308 pg of TXB2 per
200,000 microglia per 70 min, P < 0.05, n = 2). Further-
more, as shown in Fig. 3B, MZB reduced OPZ-stimulated
O2
- generation (IC50 = 4.17 µM) more than MZA. MZB 10
µM reduced O2
- generation to 16.5 % of control (MZB vs.
vehicle, respectively 1.5 ± 0.7 vs. 9.4 ± 0.7 O2
- nmol per
200,000 microglia per 70 min, P < 0.01, n = 2).
As shown in Fig. 2B and 3B, in contrast to MZA, MZB was
cytotoxic to neonatal brain microglia at concentrations
above 1 µM. In fact, considerable LDH release was
observed at 10 µM (88.3 ± 12 % of total LDH released by
0.1 % Triton X-100 treated-microglia, n = 5, P < 0.01).
Taken together, these data suggest that the reduction of
both O2
- and TXB2 generation resulted from both pharma-
cological and toxic effects of MZB on LPS-activated micro-
glia cells.
Effect of manzamine C on LPS-activated neonatal brain 
microglia TXB2, O2
- and LDH release
MZC differs from MZA in having a monocyclic amine ring
attached to the β -carboline moiety (Fig. 1). As shown in
Fig. 2C, MZC which was tested as a free base, was less
potent than MZA in affecting PMA-stimulated TXB2 gener-
ation (IC50 = 2.98 µM). MZC 10 µM reduced TXB2release
to 19.6 % of control (MZC vs. vehicle, respectively 677 ±
293 vs. 3,279 ± 281 pg of TXB2 per 200,000 microglia per
70 min, P < 0.01, n = 3). Similarly, as depicted in Fig. 3C,
MZC was less potent than MZA in affecting PMA-stimu-
lated O2
- generation (apparent IC50 = 3.43 µM). MZC 10
µM reduced O2
- release to 36.1 % of control (MZC vs.
vehicle, respectively 3.7 ± 2.2 vs.10.8 ± 0.6 nmol of O2
- per
200,000 microglia per 70 min, P < 0.05, n = 3).
As shown in Fig. 2C, MZC affected OPZ-stimulated TXB2
(IC50 = 3.34 µM), similar to MZA. MZC 10 µM reduced
TXB2 generation to 29.8 % of control (MZC vs. vehicle,
respectively 1,345 ± 160 vs. 4,504 ± 308 pg of TXB2 per
200,000 microglia per 70 min, P < 0.05 n = 2). Further-
more, as depicted in Fig. 3C, MZC reduced OPZ-stimu-
lated O2
- generation (apparent IC50 = 9.3 µM), higher than
MZA. MZC 10 µM reduced O2
- generation to 41.6 % of
control (MZC vs. vehicle, respectively 3.9 ± 0.3 vs. 9.4 ±
0.7 O2
- nmol per 200,000 microglia per 70 min, P < 0.05,
n = 2).
As shown in Fig. 2C and 3C, and in contrast to MZA, MZC
was cytotoxic to neonatal brain microglia though not as
much as MZB. Substantial LDH release was observed at 10
µM (59.8 ± 11 % of total LDH released by 0.1 % Triton X-
100 treated-microglia, n = 5, P < 0.05). In summary, sim-
ilar to MZB, the data suggests that the reduction of both
O2
- and TXB2 generation resulted from both pharmacolog-
ical and toxic effects of MZC on LPS-activated microglia
cells.
Effect of manzamine D on LPS-activated neonatal brain 
microglia TXB2, O2
- and LDH release
MZD differs from MZA in having a tetrahydrocarboline
group in the molecule (Fig. 1). As shown in Fig. 2D, MZD
that was tested as its hydrochloride salt, strongly affected
PMA-stimulated TXB2 generation (IC50 = 0.23 µM). MZD
10 µM reduced TXB2 release to 18.8 % of control (MZD vs.
vehicle, respectively 611 ± 342 vs. 3,279 ± 281 pg of TXB2
per 200,000 microglia per 70 min, P < 0.01, n = 3). Fur-
thermore, as shown in Fig. 3D, MZD also strongly affected
PMA-stimulated O2
- generation. MZD 0.1 µM reduced O2
-
release to 14 % of control (MZD vs. vehicle, respectively
0.7 ± 0.7 vs. 10.8 ± 0.6 nmol of O2
- per 200,000 microglia
per 70 min, P < 0.01, n = 3).
In contrast, as shown in Fig. 2D the effect of MZD on
OPZ-stimulated TXB2 generation was limited. MZD 10
µM reduced TXB2 generation to 79.9% of control (MZD
vs. vehicle, respectively 3,613 ± 469 vs. 4,504 ± 308 pg of
TXB2 per 200,000 microglia per 70 min, P > 0.05, n = 2).
Furthermore, as shown in Fig. 3D, MZD did not affect
OPZ-stimulated O2
- generation even at 10 µM.
As shown in Fig. 2D and 3D, and in contrast to MZB and
C, MZD was very cytotoxic to microglia when PMA was
used as an agonist to trigger O2
- and TXB2 release: MZD at
0.1 µM caused 61.5 ± 13 % of total LDH released by 0.1
% Triton X-100 treated-microglia (n = 5, P < 0.05). In con-
trast to the limited effect of MZD on OPZ-stimulated
microglia, the data suggests that the reduction of PMA-BMC Pharmacology 2005, 5:6 http://www.biomedcentral.com/1471-2210/5/6
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stimulated O2
- and TXB2 generation resulted from both
pharmacological and toxic effects of MZD on LPS-acti-
vated microglia cells.
Effect of manzamine E on LPS-activated neonatal brain 
microglia TXB2, O2
- and LDH release
As shown in Fig. 1, MZE differs from MZA in having a sat-
urated ketone functionality in the eight-membered amine
ring. As depicted in Fig. 2E, MZE inhibited PMA-stimu-
lated TXB2 generation with a maximum 49.4 % inhibition
observed at 10 µM (MZE vs. vehicle, respectively 1,614 ±
628 vs. 3,279 ± 281 pg of TXB2 per 200,000 microglia per
70 min, P > 0.05, n = 3). Furthermore, as shown in Fig. 3E,
MZE inhibited PMA-stimulated O2
-  generation with a
maximum 26.3 % inhibition observed at 10 µM (MZE vs.
vehicle, respectively 8.5 ± 2.1 vs.10.8 ± 0.6 nmol of O2
- per
200,000 microglia per 70 min, P > 0.05, n = 3).
As shown in Fig. 2E, MZE had limited effect on OPZ-stim-
ulated TXB2 generation, with a maximum 43.1 % inhibi-
tion at 10 µM (MZE vs. vehicle, respectively 2,594 ± 646
vs. 4,504 ± 308 pg of TXB2 per 200,000 microglia per 70
min, P > 0.05, n = 2). Similarly, as depicted in Fig. 3E,
MZE did not affect OPZ-stimulated O2
- generation even at
10 µM.
As shown in Fig 2E and 3E, cytotoxicity of MZE to micro-
glia measured as LDH release was low even at 10 µM
(MZE vs. vehicle, respectively 20 ± 6.7 % vs. 19.8 ± 7.7 %
of total LDH released by 0.1 % Triton X-100 treated-
microglia, P > 0.05, n = 5).
Effect of manzamine F on LPS-activated neonatal brain 
microglia TXB2, O2
- and LDH release
MZF differs from MZA in having a saturated ketone func-
tionality in the eight-membered amine ring and hydroxy-
lation at the C-8 position of the β -carboline ring system
(Fig. 1). As shown in Fig. 2F, MZF did not inhibit PMA-
stimulated TXB2 generation. In the presence of 10 µM MZ,
TXB2 release was 104.1 ± 24.7 % of control TXB2 genera-
tion (MZF vs. vehicle, respectively 3,202 ± 1,139 vs. 3,279
± 281 pg of TXB2 per 200,000 microglia per 70 min, P >
0.05, n = 3). Similarly, as shown in Fig. 3F, MZF did not
inhibit PMA-stimulated O2
- release. In the presence of 10
µM MZF, O2
- release was 113 ± 14.5 % of control O2
- gen-
eration (MZF vs. vehicle, respectively 12.8 ± 1.6 vs. 10.8 ±
0.6 nmol of O2
- per 200,000 microglia per 70 min, P >
0.05, n = 3).
As shown in Fig. 2F, MZF effect on OPZ-stimulated TXB2
generation was weak, with a non-statistically significant
26.2 % inhibition at 10 µM (MZF vs. vehicle, respectively
3,317 ± 121 vs. 4,504 ± 308 pg of TXB2 per 200,000 micro-
glia per 70 min, P > 0.05, n = 2). Similarly, as depicted in
Fig. 3F, MZF was minimally effective in inhibiting OPZ-
stimulated O2
- generation, only a non-statistically signifi-
cant 15.7 % inhibition observed at 10 µM.
As shown in Fig. 2F and 3F, cytotoxicity of MZF to neona-
tal brain microglia measured as LDH release was low even
at 10 µM (MZF vs. vehicle, respectively 19 ± 7.2 % vs. 19.8
± 7.7 % of total LDH released by 0.1 % Triton X-100
treated-microglia, n = 5).
Effect of manzamine A, B, C, D, E and F on hypoxanthine-
xanthine oxidase generated O2
-
In order to determine a potential scavenging effect of
MZA, B, C, D, E and F on O2
-, a standard hypoxanthine-
xanthine oxidase system was used as a cell-free source of
O2
- [21]. As shown in Fig. 4, O2
- generation by incubation
of purified xanthine oxidase with hypoxanthine was abol-
ished by superoxide dismutase. Furthermore, DMSO, the
vehicle used to prepare the manzamines, did not affect O2
-
formation (control vs. DMSO, respectively 12.3 ± 2.3 vs.
12 ± 1.1 nmoles/30 min, n = 2, P > 0.05). Similarly, MZA,
B, and E did not significantly affect O2
- generation (MZA,
B, E vs. control, respectively, 15.3 ± 4.4, 15.3 ± 2.4, 16.3 ±
2.2 vs. 12 ± 1.1 nmoles/30 min, n = 2, P > 0.05). In con-
trast, MZC, D and F appeared to enhance O2
- formation
(MZC, D, F vs. control, respectively 20.7 ± 3.1, 22.2 ± 2,
20.1 ± 3.6 vs. 12 ± 1.1 nmoles/30 min, n = 2, P < 0.05
(MZC, F), P < 0.01 MZD). Thus we conclude that the inhi-
bition of either PMA or OZ stimulated-O2
- release from
LPS-activated microglia by the manzamines was not the
result of a direct O2
- scavenging effect.
Discussion
The important role of neuroinflammation and glial acti-
vation in the pathogenesis of brain disorders has progres-
sively been established [1,2,22]. Because in vitro LPS-
activated microglia appear to mimic the functions of
activated microglia found in neuroinflammatory condi-
tions in vivo [2,23], we used LPS-activated rat microglia as
a relevant in vitro paradigm to search for marine natural
products that may modulate the enhanced release of TXB2
and O2
- from activated microglia [24]. Using this in vitro
model we have previously communicated that MZA, a sec-
ondary metabolite isolated from the Okinawan marine
sponge Haliclona sp[10], inhibited TXB2 and O2
- genera-
tion by microglia [18]. The current study extends our ini-
tial observations, and reports a structure-activity
relationship study with manzamines A, B, C, D, E and F
on both PMA and OPZ-stimulated release of TXB2 and O2
-
from LPS-activated rat neonatal microglia.
Members of the eicosanoid family (i.e. prostaglandins,
leukotrienes and thromboxanes) are important mediators
of inflammation that would appear to be play a causative
role in the pathogenesis of several CNS disorders [25-27].
Increased levels of eicosanoids have been observed inBMC Pharmacology 2005, 5:6 http://www.biomedcentral.com/1471-2210/5/6
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neurodegenerative disorders such as amyotrophic lateral
sclerosis [28], multiple sclerosis [29], ischemia and sei-
zures [30], prion diseases [31], human immunodeficiency
virus-associated dementia [32] and Alzheimer's disease
[33]. Following the seminal observation that microglia
release eicosanoids [34], numerous studies have increas-
ingly supported the notion that activated brain macro-
phages may be the main source of both prostaglandins
[33,35-39] and thromboxanes [23,37,39,40] in these
neurodegenerative diseases. Thus modulation of micro-
glia enhanced prostanoid synthesis has been investigated
as a potential drug therapeutic approach for intervention
in neuroinflammatory disorders of the CNS [36,41,42].
One possible approach to diminish enhanced eicosanoid
production has been to search for inhibitors of signal
transduction pathways involved in eicosanoid synthesis
in activated microglia [42]. In our study, we used PMA
and OPZ, agonists known to activate p44/42 and p38
mitogen-activated protein kinases in microglia [43], to
target distinct signal transduction pathways that cause
TXB2 release in rat neonatal microglia activated by an in
vitro exposure to 0.3 ng/mL of LPS for 17 hours [23]. As
shown in Fig. 2, the 6 marine-derived manzamine analogs
attenuated PMA-stimulated TXB2 generation differentially
and in the following order of decreasing potency:
MZA>MZD>MZB >MZC>MZE and F. In contrast, the
manzamine analogs inhibited OPZ-stimulated TXB2 gen-
eration with reduced potency: MZB>MZA>MZC>MZD,
MZE and MZF. Thus, with the exception of MZB and MZC
which modulated both PMA and OPZ-stimulated TXB2
release with similar potency, MZA, MZD, MZE and MZF
inhibited TXB2 release with lower potency when OPZ was
used as an agonist.
It is interesting to compare our differential results with the
MZA, B, C, D, E, and F with those reported for other agents
that have been shown to modulate microglia eicosanoid
release by targeting the cyclooxygenase I and II enzymes
which are expressed in activated rat and human microglia
[35,44]. PGE2 and TXB2 synthesis that occurs concomi-
tantly with LPS-induced activation of rat [38,45,46] and
human microglia [35], has been shown to be attenuated
by nonsteroidal anti-inflammatory drugs (NSAIDs) with
differing activities towards the two isoforms of COX.
Thus, LPS-induced microglia PGE2 synthesis was reduced
by COX-1 inhibitors: acetylsalicylic acid (aspirin) (IC50 =
3.12–10 µM) [38,46], flurbiprofen (apparent IC50 = 100
nM) [45] and indomethacin (apparent IC50 = 1 nM) [38],
and the COX-2 inhibitor NS-398 (apparent IC50 = 1–5
nM) [38]. Even though NSAIDs have been reported to
attenuate neurotoxicity in vitro [47] and neuroinflamma-
tion in animal models [48-50], an important caveat is the
fact that determining the best NSAIDs for clinical neuro-
degenerative disease management appears to remain a
matter of considerable debate in view of their well known
adverse effects [51-53]. Thus, although the molecular
mechanism by which the manzamines inhibit TXB2
release in LPS-activated cells remains currently undeter-
mined, MZA inhibited PMA-stimulated eicosanoid gener-
ation in vitro with potency similar to that of the COX-1
inhibitor indomethacin [38], potency that was higher
than that of other NSAIDs that have been reported to
modulate enhanced eicosanoid release in both activated
rat and human microglia [35,38,45,46].
The involvement of reactive oxygen species (ROS) has
been documented in CNS pathologies, such as Parkin-
son's disease, Alzheimer's disease, Huntington's disease,
Down's syndrome, cerebral ischemia and reperfusion,
amyotrophic lateral sclerosis, multiple sclerosis and men-
ingitis [54]. Prolonged exposure to ROS may potentially
damage neurons, particularly their synapses [55] as well
as oligodendrocytes, the myelin producing cell of the CNS
[56] by overriding normal CNS antioxidant defense
mechanisms, e.g. superoxide dismutase, catalase, glutath-
ione-S-transferase, glutathione peroxidase, permanently
affecting cellular function [57]. Thus the mechanism of
ROS generation by CNS leukocytes, i.e. infiltrating neu-
trophils and monocytes as well as resident microglia pro-
duction of O2
-, hydrogen peroxide and nitric oxide in
CNS, has received considerable attention since the mid-
Differential effect of manzamine A, B, C, D, E and F and  superoxide dismutase on hypoxanthine-xanthine oxidase sys- tem-generated O2
- Figure 4
Differential effect of manzamine A, B, C, D, E and F 
and superoxide dismutase on hypoxanthine-xanthine 
oxidase system-generated O2
-. Cell-free source of O2
- 
was generated by a standard hypoxanthine-oxidase system as 
described in Materials and Methods. Data are expressed as 
O2
- released (nmoles O2
-/30 min) and correspond to the 
mean ± SD of 2 representative experiments in duplicate. * P 
< 0.05, ** P < 0.01 versus control.
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1980s [2]. In fact, during the past 18 years, numerous
research groups have shown that O2
- may be generated by
microglia isolated from rat, mice, hamsters, dogs, swine
and humans, when stimulated with a variety of agonists
such as phorbol ester, opsonized zymosan, calcium iono-
phore, antiviral antibodies, antibody-coated red blood
cells and myelin (reviewed in [2]). We and others have
hypothesized that rather than scavenge ROS with antioxi-
dants, the modulation of the signal transduction mecha-
nism leading to microglia ROS generation might be
putatively a better therapeutic strategy to turn off or
reduce ROS generation that could lead to neuronal injury
[2,58,59]. As depicted in Fig. 3, the manzamine analogs
attenuated PMA-stimulated O2
- generation in the follow-
ing order of decreasing potency:
MZD>MZA>MZB>MZC>MZE and MZF. In contrast, and
similarly to their weaker effect on OPZ-stimulated TXB2
generation, all the manzamine analogs modulated OPZ-
stimulated O2
-  generation with lower potency:
MZB>MZC>MZA, MZD, MZE and MZF. Interestingly, as
shown in Fig. 4, the effect of MZD, A, B and C on PMA-
stimulated O2
- formation was not the result of any detect-
able scavenging O2
-, because none of the manzamines
inhibited a standard hypoxanthine-xanthine oxidase sys-
tem that was used as a cell-free source of O2
-. Thus,
although the exact mechanism by which the manzamines
modulate O2
-  release by microglia remains currently
undetermined, we have demonstrated that these com-
pounds clearly modulate the signal transduction pathway
that PMA triggers in microglia and ultimately leads to O2
-
generation.
It is interesting to compare our differential results with the
MZD, A, B and C with those reported for other agents that
modulate PMA-stimulated O2
- generation in microglia.
Interestingly, MZD, A, B and C demonstrated higher
potency than three clinically available agents shown to
inhibit PMA-stimulated O2
- generation: propentofylline, a
selective phosphodiesterase inhibitor (IC50  >100  µM)
[60], cabergoline, a potent and selective agonist of D2-
dopamine receptors (IC50 >100 µM) [59], and nicergo-
line, an ergoline derivative used for cerebrovascular dis-
eases (IC50 = 10–15 µM) [58]. It is noteworthy that these
agents have been proposed to confer protective effects
against neurodegenerative diseases which may involve O2
-
release by activated rat microglia.
In order to determine if the effect of the manzamines on
PMA or OPZ-triggered TXB2 and O2
- generation was either
pharmacological or toxic, we investigated LDH release
from LPS-activated rat neonatal microglia. LDH has exten-
sively been used as a marker for cell cytotoxicity [61]. The
results from our investigation appear to demonstrate that
the manzamine analogs clearly differed in their effect on
LDH release from LPS-primed microglia: MZA, MZE and
MZF generated less than 50% of maximal LDH release at
10 µM, and thus were the least toxic analogs; MZB and
MZC induced greater than 50% of LDH release at 10 µM;
while MZD showed greater than 50% of LDH release at
0.1  µM when PMA rather than OPZ was used as an
agonist, thus its toxicity contrasted with the other analogs
tested. Thus even though MZD inhibited PMA-stimulated
O2
- generation with slightly higher potency than MZA,
because MZD caused concomitant LDH release at low
concentrations (0.1 µM), the nature of the inhibitory
effect on PMA-triggered O2
- and TXB2 release, either toxic
or pharmacological, remains currently unresolved. In
summary, the in vitro studies described herein suggest that
MZA is the most potent manzamine analog of the series
investigated because both PMA-stimulated O2
- and TXB2
were potently inhibited with the lowest  concomitant
release of LDH.
It is of interest to consider the results of our structure-
activity relationship (SAR) study with the manzamines,
alkaloids characterized by a complex heterocyclic ring sys-
tem attached to the C-1 of the β -carboline moiety. From
the SAR perspective, the potent effect of MZA and D
hydrochloride salts on PMA-stimulated O2
- and TXB2 sug-
gests that the solubility or ionic forms are contributing
factors to their bioactivity. Furthermore, the fused 13-
membered macrocyclic and octahydroisoquinoline ring
system, and any substitutions in these rings would appear
to be less important for their in vitro activity. Finally,
changes such as saturation or oxidation of the β  carboline
or the 8-membered amine ring tended to decrease bioac-
tivity in both O2
- and TXB2 assays.
Taken together, our current data demonstrates that the
most potent and least toxic manzamine analog, namely
MZA, was less effective in attenuating O2
- and TXB2 from
LPS-activated microglia when the triggering agonist was
OPZ rather than PMA. Similar differential effects between
PMA and OPZ-triggered signaling have been observed
with other natural products [62]. Furthermore, the current
data suggest the following on the as yet undefined mech-
anism of action of MZA: Firstly, that the MZA molecular
target plays a critical role in O2
- and TXB2 generation initi-
ated by PMA upon binding to PKC [63,64] and activation
of the p44/42 mitogen-activated protein kinase signaling
pathway [43]; Secondly, that the MZA molecular target
probably plays a less critical role in O2
- and TXB2 release
elicited by OPZ, a ligand of the microglial cell surface
complement receptor 3 shown to activate the p38
mitogen-activated protein kinase signaling pathway [43].
Studies to determine which element is targeted by MZA in
the p38 and/or p44/42 mitogen-activated protein kinase
pathways in LPS-activated rat microglia are currently
underway in our laboratory.BMC Pharmacology 2005, 5:6 http://www.biomedcentral.com/1471-2210/5/6
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Conclusion
Our present results provide the first experimental evi-
dence to support the hypothesis that the marine-derived
β -carboline alkaloid manzamines differentially modulate
both O2
- and TXB2 generated by E. coli LPS-activated rat
neonatal microglia. Additional conclusions are the fol-
lowing: Firstly, SAR studies demonstrated that at in vitro
concentrations that were non-toxic to E. coli LPS-activated
rat neonatal microglia, MZA was the most potent inhibi-
tor of O2
- and TXB2. Secondly, although the mechanism by
which MZA inhibited PMA-stimulated TXB2 generation in
vitro is as yet unclear, its potency was similar to the COX-
1 inhibitor indomethacin [38], and thus higher than other
NSAIDs reported to modulate enhanced eicosanoid
release in both activated rat and human microglia
[35,38,45,46]. Thirdly, although the mechanism by which
MZA inhibited PMA-stimulated O2
-generation  in vitro
remains undetermined, MZA was more potent than pro-
pentofylline, a selective phosphodiesterase inhibitor,
cabergoline, a potent and selective agonist of D2-
dopamine receptors and nicergoline, an ergoline deriva-
tive used for cerebrovascular diseases, compounds which
have been proposed to confer protective effects against
neurodegenerative diseases by affecting O2
- release by acti-
vated rat microglia. Fourthly, SAR studies which demon-
strated that the ionic forms are a contributing factor to the
bioactivity of the complex manzamine heterocyclic ring
system attached to a β -carboline moiety may explain the
potent effect of MZA and D hydrochloride salts on PMA-
stimulated O2
- and TXB2. Interestingly, the fused 13-mem-
bered macrocyclic amine and octahydroisoquinoline ring
system, as well as substitutions in these rings appeared to
be a non-factor for the in vitro activity of the manzamines.
Finally, the reported pharmacokinetic properties and the
lack of significant in vivo toxicity [14] of MZA, a β -carbo-
line alkaloid whose complete synthesis has been reported
[11], would suggest that MZA is a prime candidate for fur-
ther investigation of its potential utility as a pharmacoph-
ore from which new and novel therapeutic agents for
neuroinflammatory diseases might be developed.
Methods
Reagents
LPS B (Escherichia coli 026:B6) was obtained from Difco
Laboratories (Detroit, MI); Wright Giemsa stain (modi-
fied), ferricytochrome c type III (from horse heart) (FCC),
superoxide dismutase (from bovine liver), phorbol 12-
myristate 13-acetate (PMA), zymosan and dimethyl sul-
phoxide (DMSO) were obtained from Sigma Chemical
Co. (St. Louis, MO). PMA was maintained at -80°C as a 10
mM stock solution in DMSO. Opsonized zymosan (OPZ)
was maintained at -20°C in a stock solution of 15 mg/ml
in PBS and prepared as described [65]. Dulbecco's modi-
fied Eagle medium (DMEM) with high glucose (4,500
mg/l), Hank's balanced salt solution (HBSS), penicillin
(P), streptomycin (S), trypsin (0.25%)-EDTA (1 mM) and
trypan blue were purchased from GIBCO-BRL (Grand
Island, NY); certified heat-inactivated fetal bovine serum
(FBS) was obtained from Hyclone (Logan, UT); a LPS
stock of 1 mg/ml was prepared in a 0.9% sodium chloride
nonpyrogenic solution from Baxter Healthcare Corp.
(Toronto, ONT, Canada) and then diluted with DMEM
plus 10% FBS plus P and S to the appropriate concentra-
tion used in our experiments. Both the LPS stock solution
[10 ng/ml] and dilutions were stored at -80°C, thawed
prior to each experiment and discarded after use.
LPS containment
To inactivate extraneous LPS, all glassware and metal spat-
ulas were baked for 4 hours at 180°C. Sterile and LPS-free
75- and 162-cm2 vented cell culture flasks, 24-well flat-
bottom culture clusters, 96-well cell culture clusters and
disposable serological pipettes were purchased from Cos-
tar Corporation (Cambridge, MA), while polystyrene cell
culture dishes (60 × 15 mm) were obtained from Corning
Glass Works (Corning, NY). Sterile and LPS-free Eppen-
dorf Biopur pipette tips were purchased from Brinkmann
Instruments, Inc. (Westbury, NY).
Manzamines A, B, C, D, E and F
Manzamine A (MZA) was isolated from a marine sponge
species of the genus Haliclona  collected off Manzamo,
Okinawa in waters at a depth of 30 m in April 1985 [10].
Manzamine B (MZB), manzamine C (MZC) and man-
zamine D (MZD), were isolated from a sponge of the
genus  Amphimedon  collected by SCUBA off Manzamo,
Okinawa [66]. Manzamine E (MZE) and manzamine F
(MZF) were isolated from a sponge species of the genus
Xestospongia  collected off the coast of Miyako Island,
Okinawa in June 1986 [67]. All manzamines were dis-
solved in DMSO to prepare a 10 mM stock and stored at -
80°C prior to use in the experiments.
Isolation and culture of rat neonatal microglia
All experiments were performed with adherence to the
National Institutes of Health guidelines on the use of
experimental animals and with protocols approved by
Midwestern University's Research and Animal Care Com-
mittee. To isolate rat neonatal microglia, cerebral cortices
of 1–2 day-old Sprague-Dawley rats purchased from Har-
lan (Indianapolis, IN) were surgically removed and placed
in cold DMEM + 10% FBS + 120 U/ml P and 12 µg/ml S,
the meninges carefully removed, and brain tissue minced
and dissociated with trypsin-EDTA at 36°C for 3–5 min.
The mixed astroglial cell suspension was plated in either
75- or 162-cm2 vented cell culture flasks with DMEM
medium supplemented with 10% FBS + 120 U/ml P + 12
µg/ml S and grown in a humidified 5% CO2 incubator at
36°C for 12–14 days. On day 14 and every 3–4 days there-
after, microglia were detached using an orbital shakerBMC Pharmacology 2005, 5:6 http://www.biomedcentral.com/1471-2210/5/6
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(150 rpm, 0.5 hours, 36°C, 5% CO2), centrifuged (400 ×
g, 25 min, 4°C), and microglia number and viability
assessed by trypan blue exclusion. Microglia were charac-
terized as described earlier [23]. Depending on the partic-
ular experimental protocol (see below), microglia
averaging greater than 95% viability were plated in 24-
well cell culture clusters, with DMEM supplemented with
10% FBS + 120 U/ml P + 12 µg/ml S, and placed in a
humidified 5% CO2 incubator at 36°C 18–24 hours prior
to the experiments.
Experimental protocol to study the effect of manzamines 
A – F on microglia release of TXB2 and O2
-
To study the effects of manzamines A, B, C, D, E and F on
the generation of TXB2 and O2
-, rat neonatal microglia (2
× 105 cells/24-well cell culture clusters) were treated to the
following protocol. Seventeen hours prior to the experi-
ments, microglia cells were treated with LPS (0.3 ng/ml)
in a final volume of 1 ml of DMEM supplemented with
10% FBS + 120 U/ml P + 12 µg/ml. Thereafter the media
was removed and replaced with 1 ml warm HBSS, one of
the manzamines (0.1–10 µM final concentration) or vehi-
cle (DMSO) was added, and the microglia incubated for
fifteen minutes in a humidified 5% CO2 incubator at
35.9°C. After the fifteen minute preincubation period
with either manzamines or vehicle, PMA (1 µM) or OPZ
(0.5 mg/mL) was added and microglia incubated for 70
minutes in a humidified 5% CO2 incubator at 35.9°C in
the presence of the manzamines or vehicle. The final con-
centration of DMSO did not affect microglia viability or
LDH release. O2
-, TXB2 and lactate dehydrogenase (LDH)
release were assayed as described below.
Assay for TXB2
Following the incubation of LPS-activated microglia with
HBSS, manzamines or vehicle as explained above, PMA-
(1 µM) or OPZ- (0.5 mg/mL)triggered TXB2 generation in
the culture supernatants was measured using immu-
noassays (Cayman Chemical, Ann Arbor, MI) as indicated
by the manufacturer's protocol. Results were expressed as
pg/mL produced after 70 min of PMA or OPZ stimulation.
Assay for O2
-
O2
- generation was determined by the SOD-inhibitable
reduction of FCC [23]. Briefly, PMA (1 µM) or OPZ (0.5
mg/mL)- triggered O2
- release from LPS-activated micro-
glia was measured in the presence of FCC (50 µM) and
HBSS, with or without SOD (700 Units) which inhibited
>95% of FCC reduction, during the 70 min incubation
described above. All experimental treatments were run in
triplicate and in a final volume of 1 ml. Changes in FCC
absorbance were measured at 550 nm using a Beckman
DU-650 spectrophotometer. Differences in the amount of
reduced FCC in the presence and absence of SOD were
used to determine O2
- generation and expressed in nmol
by employing the molecular extinction coefficient of 21.0
× 103 M-1 cm-1.
Experimental protocol to study the effect of manzamines 
on superoxide anion by the hypoxanthine-xanthine 
oxidase system
A standard hypoxanthine-xanthine oxidase system was
used as a cell-free source of O2
-. O2
- was generated by incu-
bation of purified xanthine oxidase (0.02 Units/ml) with
hypoxanthine (1.5 mM) at 37°C [21]. O2
- formation was
assessed spectrophotometrically as the increase in absorb-
ance at 550 nm associated with the SOD (30 U/mL)-
inhibitable reduction FCC (50 µM) as described above for
rat microglia O2
- generation and expressed in nmoles/30
minutes.
Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) release from microglia was
determined spectrophotometrically as described else-
where [9]. Microglia LDH release was expressed as a per-
centage of total LDH. Total LDH resulted from 0.1%
Triton X-100-lysed microglia cells (intracellular LDH)
plus LDH released to the extracellular medium.
Statistical analysis of the data
Data were analyzed with the Prism® software package pur-
chased from GraphPad (San Diego, CA.). One-way analy-
sis of variance followed by Dunnett's test was performed
on all sets of data. Manzamine-treated groups were com-
pared with the vehicle-treated group, shown as 0 or con-
trol in the corresponding figures. Differences were
considered statistically significant at p < 0.05 and reported
in each figure legend.
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